NZ741742A - Prostate-associated antigens and vaccine-based immunotherapy regimens - Google Patents

Prostate-associated antigens and vaccine-based immunotherapy regimens

Info

Publication number
NZ741742A
NZ741742A NZ74174213A NZ74174213A NZ741742A NZ 741742 A NZ741742 A NZ 741742A NZ 74174213 A NZ74174213 A NZ 74174213A NZ 74174213 A NZ74174213 A NZ 74174213A NZ 741742 A NZ741742 A NZ 741742A
Authority
NZ
New Zealand
Prior art keywords
vaccine
prostate
associated antigens
based immunotherapy
immunotherapy regimens
Prior art date
Application number
NZ74174213A
Inventor
Joseph John Binder
Helen Kim Cho
Michael Robert Dermyer
Karin Ute Jooss
Brian Gregory Pierce
Joyce Tsi Tan
Van To Tsai
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ741742A publication Critical patent/NZ741742A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides a pharmaceutical product comprising (1) a vaccine comprising an antigen construct, and (2) a CTLA-4 inhibitor, wherein the antigen construct comprises a nucleotide sequence encoding an immunogenic PSMA polypeptide selected from the group consisting of: (i) a polypeptide consisting of amino acids 15-750 of the amino acid sequence of SEQ ID NO: 1; and (ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 9.
NZ74174213A 2012-05-04 2013-04-29 Prostate-associated antigens and vaccine-based immunotherapy regimens NZ741742A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642844P 2012-05-04 2012-05-04
NZ71949913 2013-04-29

Publications (1)

Publication Number Publication Date
NZ741742A true NZ741742A (en) 2019-11-29

Family

ID=68652888

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ74166713A NZ741667A (en) 2012-05-04 2013-04-29 Prostate-associated antigens and vaccine-based immunotherapy regimens
NZ74174213A NZ741742A (en) 2012-05-04 2013-04-29 Prostate-associated antigens and vaccine-based immunotherapy regimens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ74166713A NZ741667A (en) 2012-05-04 2013-04-29 Prostate-associated antigens and vaccine-based immunotherapy regimens

Country Status (1)

Country Link
NZ (2) NZ741667A (en)

Also Published As

Publication number Publication date
NZ741667A (en) 2019-11-29

Similar Documents

Publication Publication Date Title
MX2013008836A (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof.
CA2817709C (en) Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
MX2018008135A (en) Influenza nucleic acid molecules and vaccines made therefrom.
CL2013001124A1 (en) Isolated antibody or a protein comprising an antigen binding portion of an antibody directed against a cd40 polypeptide; pharmaceutical composition comprising said antibody; nucleic acid encoding the antibody; cloning vector; antibody production process.
MX340014B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012009000A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2014004214A (en) Recombinant self-replicating polycistronic rna molecules.
PE20142406A1 (en) ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES
MX2017005642A (en) Anti-ang2 antibodies and methods of use.
MX2020001385A (en) Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same.
MX355501B (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria.
EA201290675A1 (en) VACCINE VECTORS AND METHODS OF STRENGTHENING IMMUNE RESPONSES
WO2015107363A3 (en) Mycobacterial antigen composition
MY169049A (en) Microorganisms for producing putrescine and process for producing putrescine using them
WO2015086354A3 (en) Novel promiscuous hpv16-derived t helper epitopes for immunotherapy
MX2019007924A (en) Influenza vaccines.
MX2016006586A (en) Identification of a novel b cell cytokine.
NZ741742A (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
EA201391669A1 (en) PROTEIN F - NEW ADHESIN HAEMOPHILUS INFLUENZAE, THE CAPABLE TO BIND LAMININ AND VITRONECTIN
PL391384A1 (en) Ribosomal P protein complex of Plasmodium falciparum as an antigen of malarial pathogen and process for the preparation of this antigen and expression cassette, especially for this process
PL406631A1 (en) Antigen, influenza vaccine, vaccine production system, method for producing antigen and application of the antigen determined above for the production of the influenza vaccine
NZ608889A (en) Vaccines based on peptides of the complement protein c5a
NZ605799A (en) Wdrpuh epitope peptides and vaccines containing the same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2021 BY AJ PARK

Effective date: 20200327

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2022 BY THOMSON REUTERS

Effective date: 20210313

LAPS Patent lapsed